연구용
제품 번호S1180
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| Sf-21 | Kinase Assay | 18.75 μM | 60 min | DMSO | Inhibition of N-terminal GST-tagged TNKS2 expressed with IC50 of 0.0053 μM | 23879431 |
| HEK293T | Function Assay | DMSO | Inhibition of Wnt signaling assessed as inhibition of forskolin-induced cAMP response element activation with IC50 of 0.078 μM | 23879431 | ||
| HEK293T | Function Assay | 10 μM | DMSO | Inhibition of beta-casein-dependent canonical Wnt3 pathway with IC50 of 0.051 μM | 22191557 | |
| HEK293T | Function Assay | 24 h | DMSO | Inhibition of mouse Wnt3A signaling with IC50 of 0.078 μM | 22260203 | |
| SW480 | Function Assay | 10 μM | 24 h | DMSO | Stabilization of Axin2 with EC50 of 0.371 μM | 22260203 |
| HEK293T | Function Assay | 50 μM | DMSO | Has no Effect on forskolin-induced cAMP signaling in human HEK293T cells coexpressing CRE | 22260203 | |
| IEC-6 | Function Assay | 6 h | Antagonist activity at Beta-catenin/TCF assessed as inhibition of Wnt-3a-induced axin2 expression with IC50 of 0.64 μM | 24060489 | ||
| IEC-6 | Function Assay | 6 h | Antagonist activity at Beta-catenin/TCF assessed as inhibition of Wnt-3a-induced lgr5 expression with IC50 of 2.9 μM | 24060489 | ||
| DLD1 | Function Assay | 20 μM | 24 h | DMSO | Inhibition of tankyrase assessed as inhibition of TCF-dependent transcriptional activity | 24527792 |
| DLD1 | Cytotoxic Assay | 20 μM | 10 d | DMSO | Cytotoxicity assessed as growth inhibition | 24527792 |
| VERO | Function Assay | 25 μM | DMSO | Disturbes PAR belt synthesis, affecting the actin cytoskeleton, cell shape and cell adhesion | 25332845 | |
| HeLa | Function Assay | 10 μM | 48 h | Reduction of cytoplasmic distribution and nuclear translocation of β-catenin | 25061499 | |
| SiHa | Function Assay | 10 μM | 48 h | Reduction of cytoplasmic distribution and nuclear translocation of β-catenin | 25061499 | |
| HEK293 | Function assay | Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin, IC50 = 0.078 μM. | 23844574 | |||
| DLD1 | Function assay | 24 hrs | Inhibition of tankyrase in human DLD1 cells assessed as reduction in Wnt activity after 24 hrs by TCF-luciferase reporter gene assay, IC50 = 0.707 μM. | 25299683 | ||
| Sf21 | Function assay | 2 hrs | Inhibition of N-terminal GST-tagged human TNKS-2 (849 to 1166 residues) expressed in in insect sf21 cells preincubated for 2 hrs followed by substrate addition measured after 30 mins, IC50 = 0.017 μM. | 27163581 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| A549 | Growth inhibition assay | 72 hrs | Growth inhibition of human A549 cells after 72 hrs by MTT assay, IC50 = 12.3 μM. | 29934219 | ||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 312.31 | 화학식 | C14H11F3N2OS |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 284028-89-3 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | NVP-XAV939 | Smiles | C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F | ||
|
In vitro |
DMSO
: 12 mg/mL
(38.42 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
TNKS2
(Cell-free assay) 4 nM
TNKS1
(Cell-free assay) 11 nM
|
|---|---|
| 시험관 내(In vitro) |
XAV-939 specifically inhibits tankyrase PARP activity. This compound dramatically decreases DNA-PKcs protein levels, confirming the critical role of tankyrase poly-ADP-ribosylation activity in maintaining stability of the DNA-PKcs protein. The greatest reduction of DNA-PKcs protein levels (< 25% relative expression compared to DMSO treated controls) occurs at 12 hours with 1.0 μM exposure. Treatment of human lymphoblasts with 1.0 μM this chemical results in marked elevation of tankyrase 1 levels. This agent is axin stabilizing agent. It stimulates beta-catenin degradation by stabilizing axin, the concentration-limiting component of the destruction complex. This compound stabilizes axin by blocking the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. This chemical deregulates the Wnt/b-catenin pathway which has been implicated in many cancers. |
| 생체 내(In vivo) |
XAV-939 (NVP-XAV939) selectively inhibits Wnt/β-catenin-mediated transcription through tankyrase1/2 inhibition. |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | β-catenin / E-cadherin / N-cadherin β-catenin / c-Myc / cyclin D1 / E-cadherin / N-cadherin / Vimentin |
|
31060551 |
| Immunofluorescence | β-catenin / E-cadherin Actin / PAR Hes1 / β-catenin / p-STAT3 |
|
31060551 |
질문 1:
I want to inject it (Cat # S1180) into mice through I.P. and just wonder what kind of solvent/solution I can use for this compound.
답변:
S1180 can be dissolved in 4% DMSO+corn oil at 1 mg/ml as a clear solution. When preparing the solution, please dissolve it in DMSO clearly first. You can sonicate and warm this compound in water bath at about 45 degree to help dissolving. Then dilute with corn oil.